背景：目前最常使用症狀導向或固定劑量的方式治療酒精戒斷症狀。本研究是在精神科病房中，比較使用症狀導向及固定劑量處理酒精戒斷症狀的療效及差異。方法：利用病歷回顧的方式，分析 60位診斷符合 DSM-IV-TR酒精依賴的病人（30位使用症狀導向治療、30位使用固定劑量治療）。比較兩組病人酒精戒斷症狀的改善程度及 benzodiazepine 的使用劑量。本研究以酒精戒斷臨床量表中文版 (CIWA-Ar-C) 評估並追蹤住院期間病人的酒精戒斷嚴重度。結果：雖然使用症狀導向療法的病人在入院首日之平均酒精戒斷症狀較固定劑量療法的病人嚴重 (CIWA-Ar-C 15.2 vs. 9.4, p < 0.001)，但治療兩天後後兩組酒精戒斷嚴重度便呈現沒有差異。接受症狀導向療法的病人比固定劑量療法者使用顯著較少的 benzodiazepine（前三日用量：10.3 ± 4.5 vs. 23.1 ± 9.0 毫克；一週用量：18.0 ± 6.9 vs. 47 ± 18.8 毫克，p < 0.001）。結論：相同於以往文獻中有關內科單位治療酒精戒斷症狀的結果，我們的研究顯示在精神科病房中，比較症狀導向療法與固定劑量療法，二者處理酒精戒斷症狀療效相當，但前者所開立的 benzodiazepine總藥量顯著減少。

Currently, mental health problems account for approximately 45% of the burden of disease among the 10-25 year age group world-wide, with one in every four young people experiencing a diagnosable mental disorder each year. Although we all too often accept mental ill-health in young people as a normal part of adolescence, this should not be the case. Mental health problems are not a trivial threat; they have numerous negative consequences in both the short and long term. Furthermore, there is good evidence to suggest that the distress and disability associated with mental ill-health in young people can extend well into the future. Promoting mental wellbeing, and reducing the risk and impact of mental and substance use disorders for young people are therefore an urgent global health, social and economic challenges, which has finally begun to be taken up. Here, we discuss innovative service reforms that aim to improve young people’s access to evidence-based mental health care, with a focus on early and pre-emptive intervention. Service reforms like these have the potential to greatly improve the mental health, wellbeing, and productivity of young people, and thus our wider society, now, and in the future.